New Standard for Unresectable Hepatocellular Carcinoma?
SAN FRANCISCO — After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed. Patients who received durvalumab (Imfinzi) plus bevacizumab (Avastin) in addition to TACE had a median progression-free survival (PFS) of 15.0 months as compared with 8.2 months for TACE […]
IMRT Best for Locally Advanced NSCLC, Study Suggests
SINGAPORE — Intensity-modulated radiation therapy (IMRT) should be the radiation technique of choice for unresectable locally advanced non-small lung cancer (NSCLC), a secondary analysis of a randomized trial suggested. In the study, IMRT resulted in similar survival outcomes compared with 3D conformal radiotherapy (3D-CRT), but with less severe lung toxicity and radiation exposure to the […]
Transplant May Be Reasonable for Certain CRC Patients With Liver Mets
For a select group of patients with colorectal cancer and unresectable liver metastases, liver transplant may be a reasonable option, according to results from a prospective, nonrandomized controlled cohort study. Overall, among 61 patients who underwent liver transplant, the median disease-free survival (DFS) was 11.8 months (95% CI 9.3-14.2), with a 5-year DFS rate of […]
Trial Suggests Optimal Approach to Unresectable CRC Liver Mets
For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the “preferred” systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary tumor, according to a phase III randomized trial. Among these patients, the median progression-free survival (PFS) was 9.0 months in those receiving FOLFOX or FOLFIRI […]